Research Reports

Medgenome Unlisted Shares

Medgenome company logo

Medgenome Share Price

DMAT

PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX

High

₹2,328

Low

₹2

Return

-

Buy Sell Medgenome Unlisted Shares

As of May 23, 2026, Medgenome Labs, Unlisted Shares are trading at ₹2,444.40 per share and face value is ₹10.00/share, with a 52-week high of ₹2,328.00 and 52-week low of ₹2,328.00. The minimun lot size is None shares, and the shares are traded on .

ISIN

info icon

INE00K701014

Face Value

info icon

10

Total Shares

info icon

24,88,893

Market Cap

info icon

608.39 Cr

Sector

info icon

Health Care

Sub-sector

info icon

Hospitals & Diagnostics Centres

Category

info icon

Soonicorn

About Medgenome

Company Overview:

  • MedGenomeis a global leader in Genetic Testing services, Genomics Research, and drug discovery solutions. It operates a multi-pronged business model that capitalizes on the growing demand for personalized medicine and genetic insights.
  • MedGenome has been committed to delivering world-class genomic solutions with greater precision and accuracy to empower every human being for better management of their health since 2013. MedGenome utilizes advanced technologies like Next-Generation Sequencing (NGS) for in-depth genetic analysis, aiding in complex diagnosis and personalized treatment plans. 
  • MedGenome is the only CAP-accredited Genetic testing lab in India that offers 1300+ genetic tests backed by the best and the latest testing technologies available across the world. MedGenome is dedicated to bringing the best precision testing solutions for quicker and smarter diagnosis of complex diseases. It operates the largest College of American Pathologists (CAP) accredited Next-Generation Sequencing (NGS) lab in South East Asia housing cutting-edge genome sequencing platforms such as Illumina's NovaSeq, HiSeq X, MiSeq, etc.
  • MedGenome actively engages in research and development services, partnering with pharmaceutical companies and research institutions. This segment offers various services like collaborating on projects related to drug discovery, pharmacogenomics, and biomarker development; storing and managing biological samples for future research endeavors; and providing expertise and infrastructure to conduct genomics and personalized medicine trials.
  • MedGenome recognized the value of strategic partnerships and collaboration with various entities including hospitals and clinics which expands their market reach and allows them to offer comprehensive care solutions to patients; pharmaceutical and research institutions which facilitate joint research projects, drug development initiatives, and clinical trials, accelerating advanced in the filed; technology companies which allow MedGenome to develop innovative solutions for data analysis, genetic testing, and personalized medicine applications.
  • MedGenome Labs Limited was incorporated on 8 April 2013, with its registered office at No. 258/A,3rd Floor Narayana Nethralaya, Narayana Health City, Hosur Road, Bommasandra Bangalore Bangalore KA 560099 IN.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Medgenome Media

News

Articles

Videos

‘Geographical expansions, augmented investments for new solutions to remain key focal areas for MedGenome’

‘Geographical expansions, augmented investments for new solutions to remain key focal areas for MedGenome’

07 Oct 2023

Financial Express

MedGenome acquires Illumina’s NovaSeq X Plus; launches Genome Sequencing Test

MedGenome acquires Illumina’s NovaSeq X Plus; launches Genome Sequencing Test

09 Jul 2023

Financial Express

MedGenome, backed by Sequoia Capital, acquires Delhi-NCR based Prognosis Laboratories

MedGenome, backed by Sequoia Capital, acquires Delhi-NCR based Prognosis Laboratories

25 May 2023

The Economic Times

Frequently Asked Question (FAQs)

Where can I find the annual report of Medgenome Labs Ltd?

The annual report of Medgenome Labs Ltd is available in the annual report section.

How to buy Medgenome Labs Unlisted Shares?

Please find below the procedure for buying Medgenome Labs Unlisted Shares at Planify.
• 1. You confirm booking of Medgenome Labs Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling Medgenome Labs Unlisted Shares is 6 months after listing. Hence you can’t sell Medgenome Labs Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

What is the lock-in period of Medgenome Labs Unlisted Shares?

Lock-in period of Medgenome Labs Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Medgenome Labs Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Medgenome Labs Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

See More

Medgenome

₹ 2,444.4

cartIcon